Braftovi outdoes Tafinlar in colorectal cancer
US approval gives Pfizer the first and second-line settings.
November's CHMP meeting sets up a GSK-Novartis battle
Novartis' Jakafi faces competition from GSK's momelotinib, while Astra looks over its shoulder at Merck in biliary tract cancer.
